Abbott presented new data at the AACR 2026 meeting showing that its Cancerguard test, which uses a multi-biomarker approach combining methylation and protein signals, enhances early detection of multiple cancers. The test demonstrated broader and more accurate detection across cancer stages, with each biomarker contributing uniquely. Additionally, the DETECT-A study, recognized with an AACR award, showed long-term positive outcomes where patients treated for early-stage cancers remained cancer-free after four years. These findings highlight the potential of multi-cancer early detection tests to improve cancer screening and patient outcomes, especially for cancers lacking routine screening options.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
